April 19: The Week in Cancer News
A urine test may help grade prostate cancers without biopsies, and states look for savings and better health in palliative care.
Progress Against Cancer
A urine test may help grade prostate cancers without biopsies, and states look for savings and better health in palliative care.
The FDA has approved the ALK inhibitor alectinib for surgically resectable NSCLC. The U.S. Food and Drug Administration (FDA) has approved alectinib (Alecensa) for use after the surgical removal of a non-small cell lung...
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
A poster at the AACR Annual Meeting 2024 examined a video that increased awareness of prostate cancer.
More cancer patients are enrolling in clinical trials, and sentinel node biopsies alone may be adequate for some early-stage breast cancers.
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for adult patients with unresectable...
The recently approved immunotherapy Amtagvi uses a patient’s own immune cells to destroy advanced melanoma.
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
First CAR T-cell therapy approval in chronic lymphocytic leukemia, and Environmental Protection Agency announces a complete ban on asbestos use in manufacturing.
Mirvetuximab soravtansine-gynx was approved for certain ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved mirvetuximab soravtansine-gynx (Elaher) for patients with ovarian epithelial, fallopian tube, or peritoneal cancers...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More